恩度联合埃克替尼对晚期非小细胞肺癌患者化疗敏感性、肿瘤标志物及预后的影响OA北大核心CSTPCD
Effect of endostatin in combination with icotinib on chemotherapy sensitivity,tumor markers,and prognosis in patients with advanced non-small cell lung cancer
目的 探讨恩度联合埃克替尼对晚期非小细胞肺癌(NSCLC)患者化疗敏感性、肿瘤标志物及预后的影响.方法 选取2019年1月至2020年8月我院收治的88例晚期NSCLC患者,随机分为观察组和对照组,每组44例.2组均采取培美曲塞+顺铂(PP)化疗,同时对照组给予埃克替尼治疗,观察组给予恩度联合埃克替尼治疗.观察2组临床疗效、肿瘤标志物[糖类抗原(CA)50、癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA)21-1]、T淋巴细胞亚群、miR-34b、miR-204-5p、miR-158-5p表达水平,以及酪氨酸蛋白激酶2(JAK2)/信号转导和转录激活因子3(STAT3)信号通路和不良反应.结果 2组临床总缓解率比较无统计学差异(P>0.05).治疗后,观察组血清CA50、CEA、CYFRA21-1水平低于对照组(P<0.05);CD3+、CD4+、CD4+/CD8+水平高于对照组,CD8+低于对照组(P<0.05);miR-34b、miR-204-5p、miR-158-5p表达水平高于对照组,J AK2、STAT3mRNA表达水平低于对照组(P<0.05);无进展生存期高于对照组(P<0.05).结论 恩度联合埃克替尼治疗晚期NSCLC疗效确切,可提高患者化疗敏感性及免疫功能,其作用机制可能与抑制JAK2/STAT3信号通路有关.
Objective To investigate the effects of endostatin combined with icotinib on chemotherapy sensitivity,tumor markers,and prognosis in patients with advanced non-small cell lung cancer(NSCLC).Methods A total of 88 patients with advanced NSCLC admitted to our hospital from January 2019 to August 2020 were selected and randomly assigned to two groups,with 44 patients in each group.The patients in both groups were treated with pemetrexed+cisplatin(PP)chemotherapy,whereas those in the control group were administered echitinib and those in the observation group was treated with endostatin combined with icotinib.Patients in the two groups were assessed for clinical efficacy,tumor markers[carbohydrate antigen(CA)50,carcinoembryonic antigen(CEA),cytokeratin 19 fragment(CYFRA)21-1],T lymphocyte subsets,microRNA expression levels(miR-34b,miR-204-5p,and miR-158-5p)and tyrosine protein excitation.We also examined janus kinase 2(JAK2)/signal transducer and activator of transcription 3(STAT3)signaling pathways,along with adverse reactions.Results We detected no significant differences between the two groups with respect the total response rate(P>0.05).Following treatment,the levels of serum CA50,CEA,and CYFRA21-1 in the observation group patients were found to be lower than those of patients in the control group(P<0.05).Similarly,the levels of CD3+,CD4+,CD4+/CD8+in observation group patients were higher than those in the control group patients,whereas the levels of CD8+were lower than those in the control patients(P<0.05).Furthermore,the expression levels of miR-34b,miR-204-5p,and miR-158-5p in the observation group patients were higher than those in the control group patients,whereas contrastingly,the levels of J AK2 and STAT3 mRNA expression were lower than those in the control group(P<0.05).In addition,the progression-free survival of the observation group patients was higher than that of control group patients(P<0.05).Conclusion The combination of endostatin and icotinib has clear therapeutic efficacy in patients with advanced NSCLC,which can con-tribute to enhancing their sensitivity to chemotherapy and immune function.We speculate that the underlying mechanisms of action may be associated with a reduction in the activity of the JAK2/STAT3 signaling pathway,which is beneficial for patient prognosis.
陈涛利;柳云飞;王延朋;隋俊召;王启船
南阳市第二人民医院肺部肿瘤科,河南 南阳 473000
临床医学
埃克替尼恩度晚期非小细胞肺癌化疗敏感性肿瘤标志物免疫功能
icotinibendostatinnon-small cell lung cancerchemotherapy sensitivitytumor markerimmunological functioning
《中国医科大学学报》 2024 (007)
610-615 / 6
河南省医学科技攻关计划(联合共建)(LHGJ20201469)
评论